HCPs and women should be aware that estrogen therapy has beneficial cardiometabolic effects, which can influence cardiovascular disease risk. Non-use of HT is associated with an increased risk of cardiovascular events and mortality, and HT is therefore recommended until the usual age of menopause.

STRONG ⊕⊕◯◯